<DOC>
	<DOCNO>NCT01383603</DOCNO>
	<brief_summary>Cat allergy increasingly prevalent condition , affect 10-15 % patient allergic rhinoconjunctivitis . Cat-PAD novel , synthetic , allergen derive peptide desensitise vaccine currently develop treatment cat allergy . At present , efficacy immunotherapy ( peptide otherwise ) establish conclusion therapy . No reliable predictive biomarkers clinical efficacy currently exist . Identification surrogate biomarkers clinical efficacy , would facilitate clinical development peptide immunotherapy vaccine , addition provide improve understanding underlying molecular mechanism efficacy , thus provide new lead therapeutic intervention .</brief_summary>
	<brief_title>Identification Potential Biomarkers Peptide Immunotherapy . Part 2 - Gene Array Analysis</brief_title>
	<detailed_description />
	<criteria>Male female , age 1865 year . Weight &gt; 50 kg . A minimum 1year documented history rhinoconjunctivitis exposure cat . Positive skin prick test cat allergen . Subjects must regular exposure cat normal living work circumstance throughout course study . Minimum qualify rhinoconjunctivitis symptom score History asthma History anaphylaxis cat allergen History allergen immunotherapy previous 10 year , previous 3 year preseasonal immunotherapy treatment History significant disease disorder ( e.g . autoimmune , cardiovascular , pulmonary , gastrointestinal , liver , renal , neurological , musculoskeletal , endocrine , metabolic , neoplastic/malignant , psychiatric , major physical impairment , severe atopic dermatitis )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Cat Allergy</keyword>
	<keyword>Rhinoconjunctivitis</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Cat-PAD</keyword>
</DOC>